Lipocine price to sales ratio LPCN

Market value divided by revenue over the last twelve months, since 2019.

Today, Oct 23, 2026: 7.6×
8-year median: 6.7×
Against its 8-year history: 51st; percentile: 0 is its lowest day, 100 its highest
8-year range: -10.8× to 193×
Peer median: 0.9×

Lipocine's price to sales ratio is 7.6× as of Oct 23, 2026.

That is above its 8-year median of 6.7×, close to the middle of its last 8 years.

Over that time it ranged from -10.8× in Apr 2024 to 193× in May 2020.

The median for 3 large drugmakers of a similar size is 0.9×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	7.6×	7.6×	27.1×
2025	6.7×	1.4×	6.7×
2024	3.2×	-10.8×	10.8×
2023	-4.8×	-5.1×	47.8×
2022	n/m a value too high to mean anything
2021	n/m a value too high to mean anything
2020	193×	63.1×	193×
2019	54.7×	52.3×	129×

Against its peers

Companies in Drug Manufacturers - General nearest Lipocine's size, closest first, today.

Company	Price to sales ratio
LPCNLipocine	7.6×
ATNMActinium Pharmaceuticals	n/m
SPROSpero Therapeutics	1.4×
LFVNLifevantage	0.4×
Peer median	0.9×

Where Lipocine ranks

#96of 157Large drugmakers with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Lipocine

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.